Deutsche Bank lowered the firm’s price target on 10x Genomics to $60 from $65 and keeps a Buy rating on the shares. The analyst adjusting 2024 estimates for the Xenium pull-forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- 10x Genomics price target raised to $55 from $45 at Barclays
- 10x Genomics’s preliminary Q4 results ahead of Street estimates, says Canaccord
- 10x Genomics sees FY23 revenue approximately $618.7M, consensus $614.69M
- 10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
- 10x Genomics sees Q4 revenue approximately $184M, consensus $179M
